FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma MOST POPULAR Getting Better Sleep When You Have Cancer-Related Insomnia: An Expert Q&A October 3, 2023 Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Breast Cancer Patient Devotes Her Time to Driving Others to Treatment March 15, 2021 New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma July 1, 2020 Load more HOT NEWS Prognostic Significance of Lynch-like versus Sporadic MSI-H Endometrial Cancer Treated With... GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work Reflections from our chief clinician: The essential role of our research... FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer
